Inozyme Pharma, Inc. INZY
Institutional shares held
50.6 Million
2.6K
calls
5.1K
puts
Total value of holdings
$51.1M
$2K
calls
$5K
puts
Market Cap
$40.5M
40,145,700
Shares Out.
Institutional ownership
126.08%
# of Institutions
105
We take great care to ensure that the data presented and summarized in this overview for Inozyme Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INZY
View all-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$5.21 Million0.03% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$4.54 Million11.45% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$4.32 Million0.97% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.97MShares$4.01 Million1.97% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.86MShares$3.9 Million0.43% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$3.38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.63MShares$2.66 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD2.44MShares$2.46 Million0.48% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.22MShares$2.24 Million0.12% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$1.9 Million0.0% of portfolio
Latest Institutional Activity in INZY
Top Purchases
Top Sells
About INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Insider Transactions at INZY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 02
2025
|
Douglas A Treco CEO & Chairman |
SELL
Open market or private sale
|
Direct |
8,819
-17.69%
|
$0
$0.89 P/Share
|
|
Apr 01
2025
|
Douglas A Treco CEO & Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+33.39%
|
-
|
|
Mar 31
2025
|
Sanjay Subramanian SVP, CFO & Head of BD |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+7.04%
|
$0
$0.77 P/Share
|
|
Mar 31
2025
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+25.21%
|
$0
$0.77 P/Share
|
|
Sep 30
2024
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+25.88%
|
$6,840
$4.45 P/Share
|
|
Sep 30
2024
|
Douglas A Treco CEO & Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+7.1%
|
$6,840
$4.45 P/Share
|
|
Apr 02
2024
|
Douglas A Treco CEO & Chairman |
SELL
Open market or private sale
|
Direct |
7,523
-26.69%
|
$45,138
$6.94 P/Share
|
|
Apr 01
2024
|
Douglas A Treco CEO & Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+47.0%
|
-
|
|
Mar 28
2024
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+50.0%
|
$9,564
$3.33 P/Share
|
|
Sep 29
2023
|
Sanjay Subramanian SVP, CFO & Head of BD |
BUY
Grant, award, or other acquisition
|
Direct |
2,319
+7.09%
|
$6,957
$3.57 P/Share
|
|
Aug 01
2023
|
Pivotal Bio Venture Partners Fund I, L.P. |
BUY
Open market or private purchase
|
Indirect |
833,333
+17.58%
|
$3,333,332
$4.8 P/Share
|
|
Aug 01
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
833,333
+17.58%
|
$3,333,332
$4.8 P/Share
|
|
May 12
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
228,702
+5.88%
|
$1,372,212
$6.25 P/Share
|
|
May 11
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
219,230
+6.0%
|
$1,315,380
$6.48 P/Share
|
|
Mar 31
2023
|
Axel Bolte |
BUY
Grant, award, or other acquisition
|
Direct |
4,806
+1.77%
|
$9,612
$2.21 P/Share
|
|
Mar 31
2023
|
Sanjay Subramanian SVP, CFO & Head of BD |
BUY
Grant, award, or other acquisition
|
Direct |
979
+3.37%
|
$1,958
$2.21 P/Share
|
|
Mar 29
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
344,592
+9.68%
|
$1,378,368
$4.54 P/Share
|
|
Mar 28
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
156,766
+5.18%
|
$627,064
$4.16 P/Share
|
|
Mar 27
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
51,074
+1.85%
|
$153,222
$3.7 P/Share
|
|
Dec 15
2022
|
Henric Bjorn Bjarke SVP, COO |
BUY
Open market or private purchase
|
Direct |
21,500
+16.94%
|
$21,500
$1.39 P/Share
|
Last 12 Months Summary
Buy / Acquisition
33.4K
Shares
From
4
Insiders
| Grant, award, or other acquisition | 8.4K shares |
|---|---|
| Exercise of conversion of derivative security | 25K shares |
Sell / Disposition
8.82K
Shares
From
1
Insiders
| Open market or private sale | 8.82K shares |
|---|